Vascular Dementia Pipeline: Emerging Therapies and Key pharma players involved by DelveInsight | Merz Pharma, Shineway Pharmaceutical, Materia Medica Holding, Acadia Pharmaceuticals, CSPC Ouyi Pharma

Vascular Dementia Pipeline: Emerging Therapies and Key pharma players involved by DelveInsight | Merz Pharma, Shineway Pharmaceutical, Materia Medica Holding, Acadia Pharmaceuticals, CSPC Ouyi Pharma

“Vascular Dementia Pipeline”

Vascular Dementia (VaD) is one of the most common causes of dementia after Alzheimer’s disease, causing around 15% of cases. Vascular Dementia may result not only from large-vessel strokes (multi-infarct dementia) but also from ischemic lesions caused by small-vessel pathology, including lacunar strokes and incomplete white matter ischemia (subcortical ischemic Vascular Dementia), as well as from hypoperfusion caused by heart disease or circulatory disturbances. The way by which Vascular Dementia affects people varies depending on the different underlying causes and more generally from person to person. Symptoms may develop suddenly, for example after a stroke, or more gradually, such as with small vessel disease. In practical terms, the diagnosis of Vascular Dementia should be suspected in patients with significant vascular risk factors, stroke, or heart disease who exhibit abrupt changes in cognition. There is currently no cure for Vascular Dementia: the brain damage that causes it cannot be reversed.

DelveInsight’s, Vascular Dementia Pipeline Insight, 2021,” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Vascular Dementia pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. 

 

Request for free sample report: https://www.delveinsight.com/sample-request/vascular-dementia-pipeline-insight

 

Some of Vascular Dementia Companies are:

  • Merz Pharma
  • Shineway Pharmaceutical
  • Materia Medica Holding
  • Acadia Pharmaceuticals
  • CSPC Ouyi Pharmaceutical
  • Hutchison Whampoa Guangzhou Baiyunshan Chinese Medicine Company
  • Cyclerion therapeutics
  • Charsire Pharmaceutical
  • AriBio
  • And Many Others

 

Request for free sample report: https://www.delveinsight.com/sample-request/vascular-dementia-pipeline-insight

 

DelveInsight’s Vascular Dementia report covers around 10+ products under different phases of clinical development like:

  • Late stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I) along with the details of
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
  • Route of Administration

 

Some of Vascular Dementia Therapies are:

  • Akatinol Memantine
  • BAC
  • AR1001
  • And Many Others

 

Request for free sample report: https://www.delveinsight.com/sample-request/vascular-dementia-pipeline-insight

 

Current Vascular Dementia Treatment Scenario and Vascular Dementia Emerging Therapies:

  • How many companies are developing Vascular Dementia drugs?
  • How many Vascular Dementia drugs are developed by each company?
  • How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Vascular Dementia?
  • What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Vascular Dementia therapeutics?
  • What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Vascular Dementia and their status?
  • What are the key designations that have been granted to the emerging drugs?

 

Table of Contents:

Introduction

Executive Summary

Vascular Dementia: Overview

Pipeline Therapeutics

  • Comparative Analysis

Therapeutic Assessment

Vascular Dementia – DelveInsight’s Analytical Perspective

In-depth Commercial Assessment

Vascular Dementia Collaboration Deals

Late Stage Products (Phase III)

  • Comparative Analysis

Akatinol Memantine: Merz Pharma

Drug profiles in the detailed report…..

Mid Stage Products (Phase II)

BAC: Charsire Pharmaceutical

Drug profiles in the detailed report…..

Early Stage Products (Phase I)

AR1001: AriBio

Drug profiles in the detailed report…..

Inactive Products

  • Comparative Analysis

Vascular Dementia Key Companies

Vascular Dementia Key Products

Vascular Dementia- Unmet Needs

Vascular Dementia- Market Drivers and Barriers

Vascular Dementia- Future Perspectives and Conclusion

Vascular Dementia Analyst Views

Vascular Dementia Key Companies

Appendix

Request for Deatiled TOC: https://www.delveinsight.com/sample-request/vascular-dementia-pipeline-insight

 

About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +19193216187
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/report-store/vascular-dementia-pipeline-insight